PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has been ranked 25th on the prestigious Deloitte Technology Fast 500™ list. This recognition comes after the company reported an impressive 7,204% revenue growth from fiscal year 2019 to 2022.
The Deloitte Technology Fast 500, now in its 29th year, is a highly respected ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America. The list is compiled based on percentage fiscal year revenue growth over a three-year period.
To qualify for inclusion in the Technology Fast 500, companies must own proprietary intellectual property or technology sold to customers in products that contribute to the majority of the company’s operating revenues. Companies must also report base-year operating revenues of at least US$50,000 and current-year operating revenues of at least US$5 million. Furthermore, qualifying companies must have been in business for at least four years and be headquartered within North America.
Among the 87 life science companies recognized this year, Harmony Biosciences secured the 8th spot, solidifying its status as one of the fastest-growing companies across diverse sectors in North America.
“Harmony is a growth story and our remarkable success is a testament to the strength of our business and our commitment to delivering novel treatments for people living with rare neurological disorders,” stated Jeffrey M. Dayno, MD, President and Chief Executive Officer of Harmony Biosciences. “It’s an honor to be recognized as one of the fastest-growing companies in North America across industry sectors and we look forward to building upon this growth in the future.”
This recognition by Deloitte underscores Harmony Biosciences’ continued success and its commitment to innovation and growth in the life sciences sector.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.